British Co-Investment Fund

**Future Planet Capital** is a London-based **impact-led venture capital firm** founded in 2015 that specializes in backing high-growth companies emerging from the world's top universities and research ecosystems. The firm manages over $460M in assets and has deployed an additional $200M through co-investment initiatives, with a portfolio of approximately 160 companies across multiple geographies and stages. Future Planet Capital's investment strategy focuses on companies addressing UN Sustainable Development Goals, including climate change, education, health, security, and sustainable growth, with a track record of 60+ profitable exits and participation as a founding investor in eight unicorns. The firm combines deep investment expertise with strong academic connections, employing a proprietary data-driven algorithm that tracks over 500,000 inputs to source and benchmark opportunities. Future Planet Capital invests across pre-seed, seed, Series A, and growth equity stages, with typical check sizes ranging from $25,000 to $3 million, and operates with a global reach spanning Asia, Europe, the United Kingdom, and the United States. Notable portfolio companies include **Barinthus Biotherapeutics** (formerly Vaccitech), an Oxford University spinout that listed on NASDAQ in 2021 and developed the Oxford-AstraZeneca COVID-19 vaccine. The firm manages multiple funds and mandates on behalf of public and private investors, including sovereign wealth funds, pension funds, and local government pension funds, and maintains a long track record managing deep tech funds for the UK government and the British Business Bank.

British Co-Investment Fund (Future Planet Capital) invests at pre-seed, seed, Series A and growth, focuses on AI, engineering biology, quantum computing, semiconductors, climate tech, health, education, security and sustainable growth, backs founders in United Kingdom.

Visit website